Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P53671
UPID:
LIMK2_HUMAN
Alternative names:
-
Alternative UPACC:
P53671; A8K6H5; Q7KZ80; Q7L3H5; Q96E10; Q99464; Q9UFU0
Background:
LIM domain kinase 2 (LIMK2) is a pivotal serine/threonine-protein kinase involved in actin filament dynamics regulation, crucial for cell morphology, motility, and division. It operates downstream of Rho family GTPase pathways, influencing astral microtubule organization and mitotic spindle orientation via TPPP phosphorylation. LIMK2 also modulates ciliogenesis through CFL1 phosphorylation, vesicle trafficking, and YAP1 nuclear localization, impacting transcriptional repression of AURKA and PLK1.
Therapeutic significance:
Understanding the role of LIM domain kinase 2 could open doors to potential therapeutic strategies.